Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
Sponsor: University of British Columbia
Terminated
Low enrollment \& superior treatments available for diabetic macular edema including anti-VEFG therapies such as bevacizumab and ranibizumab.
Other terminated trials from University of British Columbia
Other Diabetic Retinopathy trials with similar outcome
A NA clinical study on Diabetic Retinopathy, this trial is terminated or withdrawn. The trial is conducted by University of British Columbia and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .